Summary This study reports on the development of a liposomal formulation of vincristine with significantly enhanced stability and biological properties. The in vitro and in vivo pharmacokinetic, tumour delivery and efficacy properties of liposomal vincristine formulations based on sphingomyelin (SM) and cholesterol were compared with liposomes composed of distearoylphosphatidylcholine (DSPC) 
Vincristine is a cancer chemotherapy agent that possesses therapeutic activity against a wide range of human malignancies. Since vincristine is a cell cycle-specific agent, its antitumour potency is very sensitive to the duration of its exposure to the tumour cells (Horton et al., 1988) . In view of this relationship, it is not unexpected that liposomal carriers have been employed to improve the efficacy of vincristine since the effectiveness of liposomes in extending the circulation lifetime of a wide variety of drugs is well established. Previous studies have demonstrated that the anti-tumour efficacy of liposomal vincristine increases with increasing liposome circulation lifetime and with increased retention of the encapsulated drug in the liposomes after i.v. administration (Mayer et al., 1990a (Mayer et al., , 1993 Boman et al., 1994) . Our efforts have, therefore, focused on the development of liposomal formulations of vincristine having enhanced pharmacokinetic properties and drug retention characteristics. This can be achieved by alterations in lipid and intraliposomal buffer composition.
Previous work with liposomal vincristine has been based on vesicles containing phosphatidylcholine (PC), usually egg PC or distearoyl-PC (DSPC), and cholesterol (Mayer et al., 1993) . Typically, vincristine loading into liposomes is effected using a transmembrane pH gradient encapsulation procedure employing an intraliposomal pH of 4.0 (Mayer et al., 1990b) . However, encapsulated vincristine leaks from liposomes following i.v. administration, 85-90% of the entrapped drug being released from DSPC/cholesterol liposomes within the plasma compartment within 24 h (Boman et al., 1994) . Vincristine retention within liposomes both in vitro and in vivo is significantly improved in liposomes possessing a larger transmembrane pH gradient (i.e. intraliposomal 0.3 M citrate buffer at pH 2.0), and these liposomal formulations have imp- roved efficacy against P388 tumours (Boman et al., 1994) . Further, a synergistic improvement of in vivo drug retention and anti-tumour efficacy was obtained in liposomes with the larger transmembrane pH gradient (intraliposomal pH 2.0) and containing 10 mol% of the ganglioside GM, (Boman et al., 1994) .
While the liposomal vincristine formulation employing an intraliposomal pH of 2.0 and 10 mol% GM, is therapeutically very efficacious, it is unlikely to be of utility in a clinical setting. Not only is GM1 potentially an antigenic lipid that may limit repeated administration of this formulation, but at pH 2.0 the acid-catalysed hydrolysis of the PC component of the liposomes will occur at a significant rate and is likely to limit the ability of the liposomes to maintain their membrane permeability characteristics. Table I ). Taken together, the above data suggest that SM/ Chol liposomes might exhibit properties well suited for extending the circulation lifetime of encapsulated vincristine and potentially leading to a significant improvement in its therapeutic activity.
Lipid and drug pharmacokinetics in BDFJ mice
We have examined the lipid and drug pharmacokinetics of DSPC/Chol and SM/Chol liposomal formulations of vincristine. These studies involved the determination of plasma clearance rates of both empty and vincristine-loaded liposomes. Plasma levels of empty DSPC/Chol and SM/Chol liposomes are shown in Figure 1 . Liposomes composed of SM/Chol were removed from the circulation at a rate slower than were DSPC/Chol liposomes. Specifically, the half-lives of lipid removal from the circulation, as calculated from the slopes of the ln% lipid remaining vs time, were 4.0 h for DSPC/Chol liposomes and 5.7 h for SM/Chol liposomes (r2 > 0.996). In liposomes loaded with vincristine, the clearance rates for both liposome types were slower, presumably because of the effect of the drug on the phagocytic activity of the RES (Mayer et al., 1995) . However, there was no statistical difference between clearance rates of DSPC/Chol and SM/Chol liposomes in formulations containing vincristine ( Figure 2) . Specifically, the half-lives for removal of vincristine-loaded liposomes from the circulation were 15.7 h for DSPC/Chol liposomes compared with 18.9 h for SM/Chol liposomes (Table II) . The removal of liposomes from the circulation could be accurately described by a first-order exponential process, as indicated by the linear relationship shown in the semi-log plot of Figure The anti-tumour efficacy of liposomal vincristine is associated with the amount of the drug remaining in circulation (Mayer et al., 1993; Boman et al., 1994) and, therefore, is dependent on both liposome longevity in the circulation and vincristine retention within the liposome. Free vincristine was rapidly removed from the circulation; the amount of vincristine in circulation at 4 and 24 h after injection was 30-to 80-fold lower than for liposomal vincristine (Figure 4 ). The total amount of vincristine remaining in the circulation was significantly lower for the liposomal DSPC/Chol formulations than for the SM/Chol formulation (Figure 4 ). At 72 h after i.v. injection, the amount of vincristine remaining in circulation was 0.10 ig vincristineml-' plasma for DSPC/ Chol compared with 0.67 tg vincristine ml-' plasma for SM/ Chol liposomes (Figure 4 ). The half-life for plasma vincristine levels was 8.0 h for DSPC/Chol liposomes compared with 12.1 h for SM/Chol liposomes (Table II) . The lower levels of plasma vincristine in the DSPC/Chol liposomes were primarily a consequence of the more rapid leakage of vincristine from DSPC/Chol liposomes (Figure 3) .
These pharmacokinetic studies of liposomal vincristine were extended to a formulation composed of SM/Chol/ PEG20,,-PE. PEG20o-PE is a lipid known to confer increased circulation longevity on liposomes . A significant increase in the amount of lipid remaining in circulation was achieved by the addition of 5 mol% PEG20w-PE to the SM/Chol mixtures. At 72 h after i.v. injection, 62.8 tLg lipid ml-' plasma remained in circulation for SM/Chol/PEG2WO-PE liposomes compared with 26.1 yg ml1' plasma for SM/Chol liposomes and 22.4 pig ml-' plasma for DSPC/Chol liposomes (Table II) .
This was reflected by a significant increase in the half-life for lipid clearance from the circulation to 24.0 h for SM/Chol/ PEG20W-PE liposomes. However, the presence of 5 mol% PEG20W-PE in SM/Chol liposomes also caused a significant increase in vincristine permeability. Specifically, only 13.8% of the entrapped vincristine remained in the liposomes after 72 h in the circulation, representing a half-life for vincristine leakage of 26.8 h for SM/Chol/PEG20w-PE liposomes (Table   II) . As a consequence of the higher vincristine-lipid ratio in The vincristine-lipid ratios observed in both DSPC/Chol and SM/Chol liposomes that had extravasated from the circulation to the peritoneal cavity were similar to those observed for liposomes remaining in the plasma. Specifically, the vincristine-lipid ratios observed for SM/Chol liposomes in the peritoneum were much greater than those for peritoneal DSPC/Chol liposomes ( Figure 6 ). In addition, the peritoneal vincristine-lipid ratios were similar to those observed in the plasma for both liposomal formulations ( Figure 6 ). These results suggest that the increased delivery of vincristine to the peritoneal cavity by SM/Chol formulations of vincristine, compared with DSPC/Chol formulations, was not a consequence of delivery of free vincristine that had leaked from liposomes in plasma. Rather, these data suggest that both SM/Chol and DSPC/Chol liposomes, containing vincristine, were extravasating from the circulation and accumulating at the site where the P388 cells were residing, as observed previously in similar systems (Mayer et al., 1995 Figure 7) . At a vincristine dose of 2 mg kg-', the DSPC/Chol formulation increased the median survival to 26.5 days (ILS = 141% compared with control mice receiving no treatment), however, the SM/Chol formulation was significantly more effective (P <0.05) than DSPC/Chol, with 50% of the SM/Chol treatment group surviving at 60 days after administration of the P388 tumours (median survival>48.5 days, ILS>341%; Figure 7 and Table III ). The greatest antitumour efficacy of the liposomal formulations of vincristine was observed at the 3 mg kg-' vincristine dose, at which SM/Chol-entrapped vincristine effected a 90% survival rate (ILS >445% and median survival>60 days; Table III ). The SM/Chol formulation at 3 mg kg-' vincristine had a survival curve that was significantly different (P < 0.05) from the DSPC/Chol formulation ( Figure 7 and Table III) . At a vincristine dose of 4mgkg-', both formulations had 40-50% survival at 60 days after inoculation of the P388 tumour, however at this vincristine dose the survival curves for the Liposomal vincnstine MS Webb et al occurred in the treated animals before the earliest of the tumour-related deaths in control animals (days 6-9; Figure 7 and Table III ). These deaths were consistent with vincristine toxicity, rather than the results of excessive tumour growth ( Figure 7 ). There was no indication that SM/Chol formulations were significantly more toxic than were the DSPC/Chol formulations based on the nadir animal weights following treatment (Table III) The anti-tumour efficacy of free and liposomal vincristine against A431 was closely correlated with vincristine accumulation at the tumour site (Figure 9 ). SCID mice bearing the A431 tumours that received no treatment showed a 100% increase in tumour weight within 4-5 days after treatment was initiated and required termination within 10 days when the tumour exceeded 10% of the total body weight. Tumourbearing SCID mice treated with free vincristine at 2.0 mg kg-' had a brief delay in tumour growth (100% increase in tumour weight achieved within 6-8 days) but required termination between 10 and 12 days. In contrast, treatment with vincristine encapsulated in DSPC/Chol liposomes resulted in a significant delay in tumour growth (100% increase in tumour weight at 15-20 days, termination at 21 days after treatment). This therapy was further enhanced by a single treatment of vincristine encapsulated in SM/Chol liposomes. In this treatment group a small but consistent decrease in tumour size was observed. At 15 days after injection, several tumours were palpable but unmeasurable, and by 33 days after treatment several tumours were not palpable. Of the five mice (total of ten tumours) treated with SM/Chol liposomal vincristine, one animal was killed early because of tumour ulceration, not due to tumour growth. Of the eight tumours remaining at 40 days after liposome injection, histological analysis indicated that all eight were actively dividing squamous cell carcinomas of a mass undetectable by physical examination. Therefore, treatment with SM/Chol liposomal vincristine effected a significant reduction in tumour growth, although none of the original tumours were cured. 
Discussion
Several reports have documented the ability of a variety of liposomes to decrease the toxicity and/or improve the efficacy of vincristine (Layton and Trouet, 1980; Mayer et al., 1990a Mayer et al., , 1993 Mayer et al., , 1995 Vaage et al., 1993; Boman et al., 1994) . Early studies revealed that vincristine is relatively permeable to the phospholipid membranes, a characteristic that limits the use of lipids containing unsaturated fatty acids, such as egg PC (Mayer et al., 1990a) . Subsequent investigations (Mayer et al., 1993 (Mayer et al., , 1995 Boman et al., 1994) demonstrated that the therapeutic activity of liposomal vincristine correlates with the drug circulation lifetime and results from drug carried directly to the tumour site within the lipid vehicle. Consequently, liposomes that rapidly release entrapped vincristine (i.e. egg PC liposomes) or are rapidly cleared by the reticulo endothelial system after i.v. administration have only modest pharmacological improvements over free vincristine (Mayer et al., 1993) . These observations initiated attempts to improve vincristine retention through the use of larger transmembrane pH gradients and/or the presence of GM, (Boman et al., 1994) . While these alterations optimised the therapeutic properties of liposomal vincristine, they also compromised the clinical utility of the formulations owing to problems associated with the use of GM, in human applications and with the high rate of phospholipid hydrolysis and degradation of the liposomes in low-pH buffers. We therefore examined the in vitro and in vivo properties of liposomal formulations of vincristine that are based on sphingomyelin rather than on phosphatidylcholine. This approach was based on the possibility that the amide-linked aliphatic chain of sphingomyelin would be more resistant to chemical and biological degradation than would be the ester-linked acyl chains of phosphatidylcholine (Table I) . Empty liposomes composed of SM/Chol displayed circulation lifetimes that were increased compared with DSPC/Chol liposomes (Figure 1 ). The extended circulation times for empty SM/Chol liposomes is consistent with the lower adsorption of serum proteins to SM/Chol liposomes. An inverse relationship between protein opsonisation to liposomes and circulation longevity has been reported previously (Senior et al., 1985; Hwang, 1987; Chonn et al., 1992) and is consistent with the importance of protein-liposome interaction in liposome pharmacokinetics. Extended circulation lifetimes for SM/Chol liposomes have also been observed by other workers (Allen and Chonn, 1987; Allen et al., 1989 ). However, it should be noted that previous reports employed an entrapped aqueous solute ("251-labelled tyraminylinulin) as a marker for liposome distribution. Consequently, it is possible that the apparent increase in liposome longevity in the presence of sphingomyelin (Allen and Chonn, 1987; Allen et al., 1989) (Figure 3) . The effect of sphingomyelin on vincristine retention resulted in a 6-to 7-fold increase in plasma levels of vincristine between 48 and 72 h after i.v. administration in BDF1 mice compared with the DSPC/Chol formulation of vincristine (Figure 4) . The increased levels of vincristine remaining in circulation in the plasma using SM/Chol formulations (Figures 4 and 8a) were correlated with greater amounts of vincristine delivered to the site of P388 tumour cell inoculation (the peritoneal cavity; Figure 5 ) and to subcutaneous A431 tumours grown in SCID mice (Figure 8b) (Mayer et al., 1995) . This is consistent with previous studies which have shown that the delivery of a liposomal drug to a tumour is associated with extravasation of liposomes to the interstitial, or extravascular, spaces of the tumours (Gabizon, 1992 (Gabizon, , 1994 Bally et al., 1994; Yuan et al., 1994 (Table I) , similar to the behaviour of liposomes that contain GM, (Chonn et al., 1992) or PEG-PE (Blume and Cevc, 1993) . It is interesting that the addition of PEG2,o-PE to SM/Chol liposomes resulted in the expected increase in liposome circulation longevity, however PEG2,w-PE also caused a significant increase in the leakage of vincristine from the liposomes. The net result of these effects was no enhancement of vincristine circulation longevity (Table II) . Further, the results presented here indicated that vincristine accumulation in the peritoneal cavity (an extravascular site) and anti-tumour activity against a peritoneal P388 tumour
were not affected by the addition of PEG2,"-PE to SM/Chol liposomes. The data presented here question the pharmacokinetic and therapeutic benefits obtained through the use of sterically stabilised lipids for relatively membranepermeable agents such as vincristine.
It should be noted that several reports have suggested that sphingomyelin-containing liposomes are more toxic than PCcontaining liposomes (Weereratne et al., 1983; Allen et al., 1984; Allen and Smuckler, 1985) . However, these studies, in which mice received high-dose chronic injections (10 i.p. injections during a 20 day period) of liposomes (Weereratne et al., 1983) , found that small unilamellar vesicles containing sphingomyelin were not different from either controls or similar PC-containing liposomes (Allen et al., 1984) . In addition, the observed effects (liver granulomas) also occurred in mice receiving injections of DSPC/cholesterol liposomes (Allen and Smuckler, 1985) . Our data (Table III) suggest that vincristine formulated in SM/Chol liposomes was not significantly more toxic than vincristine in DSPC/Chol liposomes. While weight loss associated with the administration of liposomal vincristine was somewhat greater than that incurred for free vincristine (Table III) , animals receiving free drug also had more rapid tumour growth,and weight gain than did the animals receiving liposomal drug. A more detailed analysis of the toxicities associated with single and multiple i.v. administrations has recently shown that liposomal vincristine is less toxic than the free drug in mice and has very similar toxicity to the free drug in beagle dogs (Kanter et al., 1994) . Overall, these results suggest that the therapeutic index of SM/Chol liposomal vincristine is significantly better than either free vincristine or vincristine encapsulated in DSPC/Chol liposomes.
In summary, we have demonstrated that liposomal formulations of vincristine based on sphingomyelin/cholesterol have several significant advantages over those based on DSPC/cholesterol. These liposomal formulations are more resistant to chemical degradation and drug release in vitro. Further, they also have improved pharmacokinetic and therapeutic characteristics. Specifically, the anti-tumour activity of vincristine can be optimised from a drug that in free form has only minimal activity against P388 ascitic tumours and A431 human solid tumours to a drug that causes cures and significant increases in lifespan. The ability to achieve these effects without the use of unusual lipids such as GM1 or sterically stabilised lipids and/or extreme pH conditions increases the likelihood that this technology will be of use for applications in a variety of human neoplasms.
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